{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"27.9","value":"14.0"},{"groupId":"OG001","lowerLimit":"16.8","upperLimit":"45.2","value":"29.5"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"15.8","value":"4.7"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"8.0","value":"0"}]}],"title":"CR with Incomplete Platelet Recovery (CRp)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"25.1","value":"11.6"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"8.0","value":"0"}]}],"title":"CR with Incomplete Blood Count Recovery (CRi)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.4","upperLimit":"33.4","value":"18.6"},{"groupId":"OG001","lowerLimit":"16.8","upperLimit":"45.2","value":"29.5"}]}],"title":"CR Plus CRp"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"CR was defined as absolute neutrophil content (ANC) ≥1000/ microliter (μL), platelets ≥100,000/μL, independence from red blood cell (RBC) and platelet transfusions over the past week, no leukemic blasts and \\<5% leukemic blasts. CRp was defined as CR criteria except platelets \\<100,000/μL.and platelet transfusion over the past week. CRi was defined as CR criteria except ANC \\<1000/μL or platelets \\<100,000/μL. Percentage of participants with CR, CRi, CRp, and CR Plus CRp based on IWG 2003 AML response criteria are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG000","title":"AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727"},{"description":"Participants with AML received IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG001","title":"AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set included all participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2.4 years","title":"AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}